Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14582839 | 1.00 | EPHX2 (0.47) | EPHX2KMT2AALDH1A1MDM4TP53 | |
| SCHEMBL30638145 | 0.91 | MDM2 (0.47) | EPHX2KMT2AALDH1A1MDM4TP53 | |
| SCHEMBL14060845 | 0.87 | PTPN1 (0.46) | EPHX2KMT2AALDH1A1MDM4TP53 | |
| SCHEMBL20099715 | 0.87 | PTPN1 (0.45) | ALDH1A1MDM4TP53CASP3PTPN1 | |
| SCHEMBL26328832 | 0.87 | PTPN1 (0.45) | ALDH1A1MDM4TP53CASP3PTPN1 | |
| SCHEMBL29516104 | 0.86 | BACE1 (0.50) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL28468556 | 0.86 | BACE1 (0.50) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL31028497 | 0.86 | HDAC1 (0.51) | EPHX2KMT2AMDM4TP53PTPN1 | |
| SCHEMBL29398876 | 0.86 | HDAC1 (0.51) | EPHX2KMT2AMDM4TP53PTPN1 | |
| SCHEMBL28468555 | 0.86 | BACE1 (0.50) | EPHX2KMT2AMDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170003289-A1 | METHODS AND MATERIALS FOR ASSESSING ENZYME-NUCLEIC ACID COMPLEXES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170003289-A1 | METHODS AND MATERIALS FOR ASSESSING ENZYME-NUCLEIC ACID COMPLEXES | RNGTT, DNASE1, POLRMT | EPHX2 2219/4885KMT2A 1502/4885ALDH1A1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.